Publications by authors named "Kristine D Harper"

Claim this Profile
A
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Michael A Nauck, Jean-Louis Frossard, Jamie S Barkin, Greg Anglin, Ingrid E Hensley, Kristine D Harper

Diabetes Care· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
Katherine R Tuttle, T Dwight McKinney, Jaime A Davidson, Greg Anglin, Kristine D Harper

Diabetes Obes Metab· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteosarcoma and teriparatide?
Kristine D Harper, John H Krege, Robert Marcus, Bruce H Mitlak

J Bone Miner Res· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comments on Initial experience with teriparatide in the United States.
Kristine D Harper, John H Krege, Robert Marcus, Bruce H Mitlak

Curr Med Res Opin· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
Pierre D Delmas, Kristine E Ensrud, Jonathan D Adachi, Kristine D Harper, Somnath Sarkar

J Clin Endocrinol Metab· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.
Michael Maricic, Jonathan D Adachi, Somnath Sarkar, Wentao Wu, Mayme Wong, Kristine D Harper

Arch Intern Med· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
Elizabeth Barrett-Connor, Deborah Grady, Andreas Sashegyi, Pamela W Anderson, David A Cox, Kristine D Harper

JAMA· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Somnath Sarkar, Bruce H Mitlak, Mayme Wong, John L Stock, Dennis M Black, Kristine D Harper

J Bone Miner Res· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis